We assessed the response to DUSP4 depletion in two BRAF-mutant nonmelanoma cell lines (the glioma line DBTRG and the colorectal carcinoma cell line, LS411N) that were sensitive to MAPK inhibitors (Fig S8). This evidence concerns the gene DUSP4 and glioma.